Level up your trading with our powerful tools and real-time insights all in one place.

Get Started

HBY

Hybridon (HBY)

Hybridon

Date:

Regulatory News

Text Search:

Sort by:

Non-Regulatory News

Showing the most relevant articles for your search:AMEX:HBY

Date	Time	Source	Headline	Symbol	Company
09/12/2005	9:12AM	PR Newswire (US)	Hybridon Changes Name to Idera Pharmaceuticals	AMEX:HBY	Hybridon
09/08/2005	10:33AM	PR Newswire (US)	Hybridon, Inc. to Present at ThinkEquity Growth Conference	AMEX:HBY	Hybridon
06/21/2005	9:00AM	PR Newswire (US)	Hybridon, Inc., to Participate in Innate Immunity Panel at the BIO 2005 Annual International Convention	AMEX:HBY	Hybridon
06/17/2005	10:05AM	PR Newswire (US)	Hybridon Announces the Appointment of Robert W. Karr, M.D. to its Board of Directors	AMEX:HBY	Hybridon
06/01/2005	2:00AM	PR Newswire (US)	Hybridon Announces Collaboration to Develop Immune Modulatory (IMO) Compounds for Asthma and Allergy	AMEX:HBY	Hybridon
05/20/2005	2:20PM	PR Newswire (US)	Hybridon Announces $5 Million Private Financing	AMEX:HBY	Hybridon
05/16/2005	9:55AM	PR Newswire (US)	Hybridon Presents Preclinical Data on Interferon-Alpha Induction by Toll-Like Receptor 9 Agonists	AMEX:HBY	Hybridon
05/16/2005	9:35AM	PR Newswire (US)	Hybridon Announces Oral Presentation of Results for Phase I Trial of IMOxine(R) at ASCO 2005	AMEX:HBY	Hybridon
05/11/2005	10:05AM	PR Newswire (US)	Hybridon Publishes Data on Novel Synthetic Agonists of Toll-Like Receptor 9	AMEX:HBY
05/03/2005	10:05AM	PR Newswire (US)	Hybridon, Inc. to Present at Rodman & Renshaw Techvest 2nd Annual Global Healthcare Conference	AMEX:HBY	Hybridon
04/18/2005	10:05AM	PR Newswire (US)	Hybridon Presents New Preclinical Antitumor Data at AACR Supporting its IMOxine Development Program	AMEX:HBY	Hybridon
03/28/2005	10:05AM	PR Newswire (US)	Hybridon Reports 2004 Financial Results	AMEX:HBY	Hybridon
03/03/2005	8:00AM	PR Newswire (US)	Hybridon's Toll-like Receptor 9 Agonist Enhances Antitumor Activity of Cetuximab in Preclinical Studies	AMEX:HBY
02/22/2005	8:01AM	PR Newswire (US)	Hybridon, Inc. to Present at BIO CEO and Investor Conference	AMEX:HBY
11/22/2004	8:00AM	PR Newswire (US)	Hybridon Provides Updated Interim Results for the Phase 1 Trial of IMOxine(TM)	AMEX:HBY	Hybridon
11/15/2004	8:00AM	PR Newswire (US)	Hybridon Announces Two Presentations at the American College of Allergy, Asthma, & Immunology Annual Meeting	AMEX:HBY	Hybridon
11/02/2004	8:00AM	PR Newswire (US)	Hybridon to Present at Two Upcoming Conferences	AMEX:HBY	Hybridon
10/26/2004	9:00AM	PR Newswire (US)	Hybridon Initiates Phase 2 Trial of Its Oncology Drug Candidate, IMOxine(TM)	AMEX:HBY	Hybridon
10/25/2004	9:01AM	PR Newswire (US)	Hybridon to Present at Rodman & Renshaw Techvest 6th Annual Healthcare Conference	AMEX:HBY	Hybridon
10/06/2004	9:01AM	PR Newswire (US)	Hybridon Appoints Dr. Naveen N. Anand as Vice President, Corporate and Business Development	AMEX:HBY	Hybridon
09/23/2004	11:24AM	PR Newswire (US)	Hybridon Appoints Alison Taunton-Rigby to Board of Directors	AMEX:HBY	Hybridon
09/14/2004	8:01AM	PR Newswire (US)	The Immune Response Corporation Presents New Phase II Clinical Data Indicating That REMUNE(R) Induces a HIV-Specific Immune Resp	AMEX:HBY	Hybridon
08/30/2004	10:15AM	PR Newswire (US)	Hybridon Announces Closing of $5.1 Million Equity Private Placement; Appointment of Sudhir Agrawal, D.Phil. as Chief Executive O	AMEX:HBY	Hybridon
08/03/2004	6:15PM	PR Newswire (US)	Hybridon Licenses Key VEGF Patents to Alnylam for Treatment of Ocular Diseases with RNAi Therapeutics	AMEX:HBY	Hybridon
07/27/2004	11:00AM	PR Newswire (US)	The Immune Response Corporation Presents Data at the International Congress of Immunology on HIV Product Candidate IR103	AMEX:HBY	Hybridon
07/22/2004	9:00AM	PR Newswire (US)	Hybridon's Immunomodulatory Oligonucleotides Demonstrate Mucosal Immune Responses and Adjuvant Activity Following Oral Administr	AMEX:HBY	Hybridon
07/15/2004	8:00AM	PR Newswire (US)	The Immune Response Corporation Presents Data Demonstrating IR103 HIV-Specific Immunologic Activity at XV International AIDS Con	AMEX:HBY	Hybridon
06/16/2004	9:00AM	PR Newswire (US)	Hybridon Inc. to Present at the Third Annual Needham Biotechnology Conference	AMEX:HBY	Hybridon
05/12/2004	9:00AM	PR Newswire (US)	Hybridon Inc. to Present at the Rodman & Renshaw Techvest Global Healthcare Conference	AMEX:HBY	Hybridon
05/10/2004	9:02AM	PR Newswire (US)	Hybridon's Immunomodulatory Drug Candidate, IMOxine(TM), Produces Immune Response in Patients with Refractory Advanced Solid Tum	AMEX:HBY	Hybridon

Showing the most relevant articles for your search:AMEX:HBY

Golden Triangle Ventures (PK)

Voip Pal Com (QB)

Marketing Worldwide (PK)

Propanc Biopharma (PK)

1812 Brewing (PK)

Code Green Apparel (PK)

RespireRx Pharmaceuticals (PK)

Intergrated Cannabis Sol... (PK)

Cann American (CE)

Delayed Upgrade Clock

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions